Literature DB >> 34609302

Mucinous Pancreatic Cysts: Comparison of Cyst Size and Location in Certain Mucinous Cyst Subgroups.

Ibrahim Hakki Köker1, Şahende Elagöz2, Zuhal Gücin2, Fatma Ümit Malya3, Hakan Şenturk1.   

Abstract

BACKGROUND: There are studies reporting that the location of intraductal papillary mucinous neoplasia (IPMN) predicts malignancy. Therefore, we evaluated the cyst location's relationship with malignancy, and the possibility of using cyst size and location to distinguish between non-main duct (non-MD)-IPMNs, mucinous cystic neoplasia (MCN), and cystic pancreatic ductal adenocarcinoma (PDAC).
METHODS: We performed a retrospective analysis of data from 122 patients with a definite cyto-histological diagnosis of non-MDIPMNs, LR-MCNs, and cystic PDACs via endoscopic ultrasound fine-needle aspiration between October 2011 and October 2020. We grouped the cyst locations as head, uncinate, neck (HUN), and corpus or tail (CT). On histology, low-grade dysplasia and intermediategrade dysplasia were considered low risk (LR), whereas high-grade dysplasia and invasive carcinoma were considered high risk (HR).
RESULTS: Of the 122 patients (61 (50%) women, median age 61.5 years (range 19-85), there were 34 (27.9%) LR-non-MD-IPMNs, 33 (27%) HR-non-MD-IPMNs, 19 (15.6%) LR-MCNs, and 36 (29.5%) cystic PDACs. We found no significant difference between LRand HR-non-MD-IPMN locations (P = .803). Low-risk non-MD-IPMNs were significantly smaller than HR-non-MD-IPMNs (P < .001), LR-MCNs (P = .002), and cystic PDACs (P < .001). The area under the receiver operating characteristic curve (AUROC) was 0.819 (95% CI: 0.716-0.902; P < .0001), and demonstrated a cyst size cut-off <2.2 cm to differentiate LR cysts, while cysts <1.6 cm had a negative predictive value (NPV) of 100% in non-MD-IPMNs.
CONCLUSION: Cyst location is not predictive of malignancy in non-MD-IPMNs. Low-risk non-MD-IPMNs were smaller than HR-non MDIPMNs, LR-MCNs, and cystic PDACs. The cyst size cut-off was 2.2 cm; however, <1.6 cm had a 100% NPV differentiating LR- from HR-non-MD-IPMNs.

Entities:  

Mesh:

Year:  2021        PMID: 34609302      PMCID: PMC8975320          DOI: 10.5152/tjg.2021.21318

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.555


  20 in total

1.  International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas.

Authors:  Masao Tanaka; Carlos Fernández-del Castillo; Volkan Adsay; Suresh Chari; Massimo Falconi; Jin-Young Jang; Wataru Kimura; Philippe Levy; Martha Bishop Pitman; C Max Schmidt; Michio Shimizu; Christopher L Wolfgang; Koji Yamaguchi; Kenji Yamao
Journal:  Pancreatology       Date:  2012-04-16       Impact factor: 3.996

Review 2.  The role of endoscopy in the diagnosis and treatment of inflammatory pancreatic fluid collections.

Authors:  V Raman Muthusamy; Vinay Chandrasekhara; Ruben D Acosta; David H Bruining; Krishnavel V Chathadi; Mohamad A Eloubeidi; Ashley L Faulx; Lisa Fonkalsrud; Suryakanth R Gurudu; Mouen A Khashab; Shivangi Kothari; Jenifer R Lightdale; Shabana F Pasha; John R Saltzman; Aasma Shaukat; Amy Wang; Julie Yang; Brooks D Cash; John M DeWitt
Journal:  Gastrointest Endosc       Date:  2016-01-13       Impact factor: 9.427

3.  American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts.

Authors:  Santhi Swaroop Vege; Barry Ziring; Rajeev Jain; Paul Moayyedi
Journal:  Gastroenterology       Date:  2015-04       Impact factor: 22.682

Review 4.  Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas.

Authors:  Masao Tanaka; Carlos Fernández-Del Castillo; Terumi Kamisawa; Jin Young Jang; Philippe Levy; Takao Ohtsuka; Roberto Salvia; Yasuhiro Shimizu; Minoru Tada; Christopher L Wolfgang
Journal:  Pancreatology       Date:  2017-07-13       Impact factor: 3.996

5.  Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies.

Authors:  Tatsuji Yogi; Susumu Hijioka; Hiroshi Imaoka; Nobumasa Mizuno; Kazuo Hara; Masahiro Tajika; Tsutomu Tanaka; Makoto Ishihara; Yasuhiro Shimizu; Waki Hosoda; Yasushi Yatabe; Yasumasa Niwa; Kenichi Yoshimura; Vikram Bhatia; Jiro Fujita; Kenji Yamao
Journal:  J Hepatobiliary Pancreat Sci       Date:  2015-08-03       Impact factor: 7.027

6.  Development and Potential Utility of a New Scoring Formula for Prediction of Malignant Intraductal Papillary Mucinous Neoplasm of the Pancreas.

Authors:  Yutaka Suzuki; Tetsuya Nakazato; Masaaki Yokoyama; Masaharu Kogure; Ryota Matsuki; Nobutsugu Abe; Toshiyuki Mori; Yasuo Ohkura; Masanori Sugiyama
Journal:  Pancreas       Date:  2016-10       Impact factor: 3.327

7.  Risk factors associated with the postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Jongwook Park; Kyu Taek Lee; Tae Hoon Jang; Yong Woo Seo; Kwang Hyuck Lee; Jong Kyun Lee; Kee-Taek Jang; Jin Seok Heo; Seong Ho Choi; Dong Wook Choi; Jong Chul Rhee
Journal:  Pancreas       Date:  2011-01       Impact factor: 3.327

8.  Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Sang H Shin; Duck J Han; Kwan T Park; Young H Kim; Jae B Park; Song C Kim
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

Review 9.  ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts.

Authors:  Grace H Elta; Brintha K Enestvedt; Bryan G Sauer; Anne Marie Lennon
Journal:  Am J Gastroenterol       Date:  2018-02-27       Impact factor: 10.864

Review 10.  The Use of Biomarkers in the Risk Stratification of Cystic Neoplasms.

Authors:  Jeremy H Kaplan; Tamas A Gonda
Journal:  Gastrointest Endosc Clin N Am       Date:  2018-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.